Stephanie Chlebus-Nick, PA
Physician Assistant · Erie, PANPI 1518927946
Payments from drug & device makers
Across 251 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$749
- Medtronic$497
- Amgen$329
- Corcept Therapeutics$247
- AstraZeneca$231
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,94099%
- Education$711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 86 | $1,080 |
| Lilly USA, LLC | 44 | $749 |
| Medtronic | 9 | $497 |
| Amgen(2 entities) | 11 | $329 |
| Corcept Therapeutics | 11 | $247 |
| AstraZeneca | 6 | $231 |
| Sanofi-aventis U.S. LLC | 8 | $207 |
| Abbott | 9 | $170 |
| Boehringer Ingelheim | 9 | $150 |
| Madrigal Pharmaceuticals | 1 | $149 |
| Teva Pharmaceuticals USA, Inc. | 7 | $128 |
| Xeris Pharmaceuticals, Inc. | 6 | $114 |
| Bayer | 6 | $104 |
| Cequr Corporation | 1 | $98 |
| UCB, Inc. | 2 | $79 |
| Merck | 3 | $57 |
| Insulet Corporation | 2 | $56 |
| Novartis | 3 | $53 |
| Neurocrine Biosciences, Inc. | 2 | $49 |
| Pfizer | 2 | $38 |
| Dexcom, Inc. | 2 | $34 |
| Amneal Pharmaceuticals LLC | 2 | $32 |
| Tandem Diabetes Care, Inc. | 2 | $29 |
| Neurelis, Inc. | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Impel Pharmaceuticals LLC | 1 | $25 |
| BETA Bionics, Inc. | 2 | $24 |
| Bioventus LLC | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Exact Sciences | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,011 in reported general payments places this provider in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 89 | $105,047 |
| RybelsusSemaglutide | 78 | $86,507 |
| TrulicityDulaglutide | 72 | $73,287 |
| JardianceEmpagliflozin | 102 | $72,224 |
| MounjaroTirzepatide | 66 | $71,694 |
| TradjentaLinagliptin | 71 | $32,170 |
| FarxigaDapagliflozin Propanediol | 32 | $21,324 |
| JanuviaSitagliptin Phosphate | 30 | $19,888 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $17,760 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $14,577 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $13,603 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 102 | $10,204 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $9,831 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $9,651 |
| Novolog FlexpenInsulin Aspart | 39 | $8,674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,080 | $195,389181 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $749 | $149,855201 claims |
| Boehringer IngelheimJardiance, Tradjenta | $150 | $104,393173 claims |
| AstraZenecaFarxiga | $231 | $21,32432 claims |
| MerckJanuvia | $57 | $19,88830 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Admelog | $207 | $10,97828 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $32 | $82184 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in Erie
- Allison BoydErie$163K
- Daniel TelegaErie$124K
- Erin CrownState College$1.5M
- Tricia BootsCranberry Twp$313K
- Melissa FerrariPhiladelphia$223K
- Jason OberdickWexford$206K
- Justine RobertsMurrysville$173K
- Joshua TrbovichWashington$144K
- Alvin KingcadePhiladelphia$101K
- Jeffrey CameronWashington$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.